Haemostatix
acquired
acquired
Stage
1
Investors
About
Haemostatix developed first-in-class clotting agents for the treatment of bleeding (haemostasis). The company was an early-stage biotechnology developer and was sold to Ergomed plc in May 2016.
Explore Haemostatix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.